Dementia Conference | Alzheimer disease Conference | Parkinson's disease | Psychiatry | Prague | Czech Republic

Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences

Theme

The Future of Dementia Care:A Global Challenge

- Dementia 2025

Welcome Message

The 17th International Conference on Dementia and Alzheimer's Disease, our upcoming Dementia Conference, is scheduled for May 08-09, 2025, in Prague, Chez Republic. We are pleased to Welcome everyone to attend.

The Future of Dementia Care:A Global Challenge is the theme of Dementia 2025, a conference that features keynote speeches, poster presentations, E-poster exhibits, oral talks, and exhibitions

Having each of you attend our esteemed Dementia 2025 conference is a wonderful honor. We are committed to offering people the most innovative solutions for health issues.

This conference is a must-attend for everyone interested in the most recent developments in mental health because it will cover everything from the foundations of mental health to the most recent clinical procedures.

At Dementia 2025, all advocates, researchers, students, and mental health professionals are welcome to share their expertise. We provide lots of chances for networking, information exchange, and teamwork.

We look forward to your valuable involvement at a meeting with world-renowned specialists on May 08-09, 2025, when we will showcase novel approaches to mental health and groundbreaking research.

Warm regards,
Jessica Louis
Program Manager
Organizing Committee | Dementia 2025

About

The focus of this two-day conference on dementia and Alzheimer's disease is specifically on medical experts who are committed to improving our knowledge and management of neurodegenerative diseases. Our main goal is to give practitioners a thorough update on the most recent advancements in dementia and Alzheimer's research, with a focus on innovative methods and pediatric considerations.

The conference's main theme, "The Future of Dementia Care: A Global Challenge," highlights both its worldwide influence and our dedication to relevance.

The conference's main focus will be on precision methods for the diagnosis, treatment, prognosis, prevention, and monitoring of Alzheimer's and dementia diseases.

Keynote addresses, panel discussions, instructional sessions, video sessions, and poster presentations are all part of the conference schedule. This event seeks to bring together scientists and doctors from around the globe by providing both virtual and in-person participation using the Webex platform. This hybrid style makes it possible to share experiences, come up with fresh concepts, build connections, and work together.

Conference format: The Dementia and Alzheimer's Conference 202 5 will be held online via the Webex platform with on-demand sessions, as well as in person in the energetic city of Prague, Chez Republic. The recordings will be accessible following the conference, regardless of whether you attend in person or participate virtually from your home or place of business. This guarantees that you can see the recordings at a later time to make up for any lectures you missed. After the conference, all lecture recordings and handouts will be accessible for six months.

Learning Goals:

Apply state-of-the-art treatment modalities and therapies in the field of Dementia and Alzheimer's.

Incorporate current evidence-based research into the treatment of neurodegenerative disorders.

Stay updated on practical applications influencing operative procedures, pharmaceuticals, and medical devices.

Understand the latest evidence-based clinical pathways and best practices.

Review patient outcomes based on peer-reviewed research.

Why to attend Dementia 2025?

Professional Development
Networking Opportunities
Access to Cutting-Edge Research
Exposure to New Products and Technologies
Continuing Education Credits
Enhance Reputation and Credibility

Target Audience:

Physicians
Surgeons
Health-care Analysts
Students, Interns and Residents
Research Faculties
Doctors and Nurses
Directors/Managers/CEO’s
Presidents & Vice Presidents
Scientists and Professors
Academic Scientists
Medical Colleges, Universities
Societies & Associations
Business Entrepreneurs
Training Institutes

Opportunities for Researchers:

To present their work through oral presentations, poster sessions, or symposiums.
Provides opportunities for researchers to publish their work in conference proceedings or special issues of journals.
Speaker presentations and poster displays

We are excited to have you attend the 17th International Conference on Dementia and Alzheimer's Disease, to work together, and to increase our understanding of these important Mental Health issues.

Past Conference

With great support from our Organizing Committee, Allied Conferences successfully completed the"16th World Congress on Dementia and Alzheimer's Disease".

First and foremost, we appreciate your faith in us and your participation in Dementia 2024, a worldwide conference focused on many aspects of Dementia, Alzheimer, Parkinson and Neurology. There are several ways to express our gratitude to you for organizing a fantastic gathering for Dementia 2024. The meeting was marked by the participation of young and inventive scientists, industrial participants, and imaginative student groups from more than 20 countries, all of whom contributed to the success of this activity.

The congress proceedings are organized using a variety of scientific and plenary meetings. The meeting began with an opening ceremony, which was followed by a series of talks by both Honourable Guests and respective Keynote Panel members. The experts who brought the subject to life via their amazing presentations and testimonies from keynote speakers and seminars

Donna de Levante Raphael | Alzheimer’s Foundation of America | USA
Soni Shrestha | Oslo Municipality | Norway
Sumanth S Hiremath | Rani Channamma University | India
Laura Ion | Selinus University of Sciences and Literature | Italy

The event brought together diverse fields of Dementia with seminars and plenary talks by the presentative from various universities and organizations

Amanda F. Rose | Cleveland Clinic Akron General | USA
Ojes Xavier | St. Albert’s College| India
Brandon Lucke-Wold | Co-Founder at SwiftScience |USA
Tamas Fulop | University of Sherbrooke | Canada
Nadya Kagansky | Tel-Aviv University affiliated | Israel
Pooja Chandrashekar | All India Institute of Speech and Hearing | India
Rahimi F | Tehran University of Medical Sciences | Iran
Omer Eladil A. Hamid | Faculty of Medicine IUA | Sudan

With the great response and feedback which we received at this event, Allied conferences are proud to announce our upcoming conference entitled "17th International Conference on Dementia and Alzheimer's Disease," scheduled to be held on May 08-09, 2025 in Prague, Chez Republic.

We would like to see your pleasant participation, constructive engagement, and support in order to make this activity a success again.

AWARD’S AND BENEFITS

“Winning isn’t everything in life; it’s the only thing.”

Make memories and share your thoughts on this fantastic platform which is loaded with a bundle of opportunities and moments to capture.

Awards:

Best poster benefits:

A unique opportunity to combine visual and oral explanations of your projects in the form of a poster presentation.
The accepted poster abstracts will be published in renowned and supporting international journals with a unique DOI given by CROSSREF.
The best posters will have the opportunity to publish their entire research paper for a reduced processing fee in supporting international journals.

Young scientist benefits

Advancing perfection and perceiving remarkable commitments made by the youthful researchers for their work done essentially during the span of study.
Find out about career advancement and the most recent research devices and technologies in your field.
Graduates are motivated by the chance to choose neighbourhood or worldwide subjects of pertinence or enthusiasm to them and build up their own logical examinations and models, drawing in locally or universally.
The Award will be given to two chosen researchers.
Chances to be a student envoy.
Chances to collaborate with partners from all over the world.
Discounts at the Allied conferences, at different worldwide venues in the future.
Chances to publish full-length articles in the conference's reputed supporting global publications of the respective congress.
The Board of Directors nominates the Best Young Scientist Award, and if they wish to publish a full-length paper, they can publish it in the supporting global journals of the respective conference with no preparation fees.

Congress Opportunities

For Researchers and Faculty Members:

Speaker Presentations
Poster Display
Symposium hosting (4–5-member team)
Workshop organizing

For Universities, Associations & Societies:

Association Partnering
Collaboration proposals
Academic Partnering
Group Participation

For Students and Research Scholars:

Poster Competition (Winner will get Best Poster Award)
Young Researcher Forum (YRF Award to the best presenter)
Student Attendee
Group registrations

For Business Delegates:

Speaker Presentations
Symposium hosting
Book Launch event
Networking opportunities
Audience participation

For Product Manufacturers:

Exhibitor and Vendor booths
Sponsorship opportunities
Product launch
Workshop organizing
Scientific Partnering
Marketing and Networking with client

Scientific Sessions/Tracks

The international scientific committee of Dementia 2025 invites participants to submit abstracts on the below-mentioned congress tracks:

Session 1: Dementia

The term dementia refers to a general deterioration in mental function that interferes with day-to-day functioning. Numerous disorders of the brain that harm nerve cells are the cause of it. Typical symptoms include mood and behavior changes, cognitive difficulties, linguistic issues, and memory loss. Although Alzheimer's disease is the most prevalent cause, it can also result from other disorders such as frontotemporal dementia, Lewy body dementia, and vascular dementia. Age, family history, and lifestyle are risk factors. There is no cure, but there are therapies that can help control symptoms and enhance quality of life.

Track 1-1: Mixed dementia

Track 1-2: Frontotemporal dementia

Track 1-3: Lewy body dementia

Track 1-4: Vascular dementia

Track 1-5: Alzheimer's disease

Session 2: Alzheimer Disease

Alzheimer's disease is a degenerative brain illness that gradually impairs cognitive and memory abilities. Millions of people worldwide are impacted by it, making it the primary cause of dementia. Memory loss, cognitive and linguistic difficulties, and behavioral and emotional disturbances are some of the symptoms. Although the precise etiology is unknown, aberrant protein accumulation in the brain is believed to be a contributing factor. Treatments are available to control symptoms and decrease the disease's course, but there is yet no cure. Age, family history, and genetics are important risk factors.

Track 2-1: Mixed dementia

Track 2-2: Early-Onset Alzheimer's Disease

Track 2-3: Hippocampal-Sparing Alzheimer's Disease

Track 2-4: Limbic-Predominant Alzheimer's Disease

Track 2-5: Typical Alzheimer's Disease

Session 3: Parkinson’s Disease

Parkinson's disease is a degenerative neurological condition that impairs mobility, leading to slow motions, stiffness, tremors, and issues with balance and coordination. It is caused by the brain's dopamine-producing nerve cells degenerating. Dopamine is a neurotransmitter that is necessary for controlling smooth muscles. Usually, the symptoms start out mildly and get worse with time. There is no known cure, but there are a number of therapies that can help control the symptoms and enhance the lives of people who are impacted.

Track 3-1: Parkinsonism Plus Syndromes

Track 3-2: Drug-Induced Parkinsonism

Track 3-3: Atypical Parkinsonism

Track 3-4: Genetic Parkinson's Disease

Track 3-5: Idiopathic Parkinson's Disease

Session 4: Neurodegenerative Diseases

Parts of the nervous system, particularly the brain, can be gradually damaged and destroyed by a group of illnesses known as neurodegenerative diseases. Degeneration of nerve cells brought on by these illnesses impairs movement, cognition, and other body processes. Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and multiple sclerosis are well-known instances. Current research attempts to identify treatments that can delay the progression of these diseases and improve the quality of life for individuals who are afflicted, despite the fact that there is currently no cure.

Track 4-1: Neurodegenerative Diseases Primarily Affecting the Brain

Track 4-2: Neurodegenerative Diseases Primarily Affecting the Motor Neurons

Track 4-3: Neurodegenerative Diseases Primarily Affecting the Myelin Sheath

Track 4-4: Neurodegenerative Diseases with Mixed Features

Track 4-5: Prion Diseases

Session 5: Stages of Dementia

Over time, dementia worsens because it is a progressive condition. It is frequently divided into phases in order to better understand its progression and arrange for appropriate treatment. People have trouble with difficult tasks and minor memory loss in the early stages. As the illness progresses, memory, cognition, language, and behavior are all affected by the worsening symptoms. People may require a great deal of assistance with everyday tasks in the later stages, and their communication skills may deteriorate dramatically.

Track 5-1: Middle Stage Dementia

Track 5-2: Early-Stage Dementia

Track 5-3: Moderately Severe Dementia

Track 5-4: Severe Dementia

Track 5-5: Early Stage

Session 6: Vascular Dementia

Damage to the brain's blood arteries, which can be brought on by conditions including diabetes, high blood pressure, heart disease, and stroke, can result in vascular dementia. The degree and location of brain injury can have a significant impact on the symptoms of vascular dementia. Memory loss, trouble thinking and solving problems, behavioral and emotional changes, and physical difficulties are typical symptoms. Vascular dementia cannot be cured, but its advancement can be slowed or prevented by managing risk factors and addressing underlying medical disorders.

Track 6-1: Post-Stroke Dementia

Track 6-2: Binswanger's Disease

Track 6-3: Mixed Cortical and Subcortical Dementia

Track 6-4: Subcortical Vascular Dementia

Track 6-5: Cortical Vascular Dementia

Session 7: Frontotemporal Dementia

A collection of brain disorders known as frontotemporal dementia (FTD) mostly affect the frontal and temporal lobes, leading to alterations in behavior, language, and personality. Although symptoms might vary greatly, they frequently include poor decision-making skills, impulsive behavior, diminished empathy, and linguistic barriers. While there isn't a cure for FTD, there are treatments that can help people manage their symptoms and improve their quality of life.

Track 7-1: Semantic Dementia

Track 7-2: Primary Progressive Aphasia

Track 7-3: Motor Neuron Disease

Track 7-4: Mixed Variant

Track 7-5: Behavioral Variant Frontotemporal Dementia

Session 8: Neuropharmacology

A field of study called neuropharmacology studies how medications affect the nervous system, with a particular emphasis on how they affect behavior, brain function, and neurotransmitter systems. Researchers and medical experts can develop novel therapies for neurological and mental disorders like anxiety, depression, Parkinson's disease, and Alzheimer's disease by examining these connections. This area is crucial for the development, clinical application, and discovery of new drugs, which advances the treatment of a range of neurological and mental health conditions.

Track 8-1: Neurotransmitter Systems

Track 8-2: Neuropsychopharmacology

Track 8-3: Neuropharmacology of Addiction

Track 8-4: Neuropharmacology of Neurodegenerative Diseases

Track 8-5: Clinical Neuropharmacology

Session 9: Geriatrics Dementia and Cognitive Disorder

The medical field of geriatrics is devoted to the treatment and well-being of senior citizens. Seniors' and their families' quality of life is significantly impacted by dementia and cognitive problems, which are common concerns in geriatric care. Dementia is the term for a reduction in mental capacity that interferes with day-to-day functioning and is frequently brought on by illnesses such as Alzheimer's disease. A broader range of problems that affect memory, thinking, and problem-solving abilities are referred to as cognitive disorders. In order to manage these illnesses and improve the well-being of older people, early detection, comprehensive examination, and appropriate therapies are essential.

Track 9-1: Alzheimer's Disease

Track 9-2: Vascular Dementia

Track 9-3: Lewy Body Dementia

Track 9-4: Frontotemporal Dementia

Track 9-5: Delirium

Session 10: Neuroepigenetics

Neuroepigenetics is the study of how experiences and environmental influences can affect brain gene expression, altering behavior, cognition, and vulnerability to neurodegenerative illnesses. Without changing the DNA sequence itself, epigenetic modifications like DNA methylation and histone acetylation can impact how genes function. Stress, nutrition, and social interactions are among of the variables that might affect these changes, which may have long-term consequences for brain function. Neuroepigenetics sheds important light on the intricate interplay between environment and heredity that shapes brain health and illness.

Track 10-1: DNA Methylation

Track 10-2: Histone Modifications

Track 10-3: Non-coding RNA

Track 10-4: Epigenetic Clocks

Track 10-5: Environmental Epigenetics

Session 11: Aging and Dementia

Everyone experiences the normal process of aging, and as people age, their risk of dementia rises. While aging does not directly cause dementia, it can exacerbate diseases like vascular dementia and Alzheimer's disease. Our brains undergo changes as we age, including the death of brain cells and the accumulation of toxic proteins, which can affect memory, thinking, and cognitive function and increase the risk of dementia. However, not all elderly people get dementia, and a person's risk of getting dementia is influenced by a number of factors, including lifestyle decisions and genetic predisposition.

Track 11-1: Alzheimer's Disease and Aging

Track 11-2: Vascular Dementia and Aging

Track 11-3: Cognitive Reserve and Aging

Track 11-4: Aging and Mild Cognitive Impairment

Track 11-5: Aging and Depression

Session 12: Role of Amyloid Protein in Alzheimer’s and Dementia

Amyloid beta (Aβ) protein is a key factor in the development of Alzheimer's disease and other types of dementia. It is a naturally occurring protein that is usually broken down and removed from the brain under normal conditions. However, in Alzheimer's disease, Aβ builds up and forms plaques between nerve cells. These plaques interfere with neuron communication, causing cell death and cognitive decline. While Aβ plays a central role in Alzheimer's, other factors, including inflammation and neurofibrillary tangles, also contribute to the progression of the disease.

Track 12-1: Amyloid Beta (Aβ) Production and Clearance

Track 12-2: Aβ Aggregation and Plaque Formation

Track 12-3: Aβ-Induced Neurotoxicity

Track 12-4: Aβ and Tau Protein Interactions

Track 12-5: Aβ as a Therapeutic Target

Session 13: Bioinformatics Approach for Dementia

The field of bioinformatics, which blends computer science and biology, offers useful resources for comprehending and treating dementia. Through the analysis of enormous volumes of genetic, genomic, and proteomic data, scientists are able to determine prospective therapeutic targets, discover genetic risk factors, and unravel the molecular mechanisms behind the course of disease. Personalized treatment regimens, accelerated drug development, and disease start prediction are all made possible by bioinformatics techniques like machine learning and artificial intelligence. To find early biomarkers and monitor the course of the disease, bioinformatics also helps with the analysis of neuroimaging data.

Track 13-1: Genome-Wide Association Studies

Track 13-2: Transcriptomics

Track 13-3: Proteomics

Track 13-4: Metabolomics

Track 13-5: Machine Learning and Artificial Intelligence

Session 14: Recent Advancements in the Diagnosis of Dementia

Early detection and accuracy have been significantly improved by recent advancements in dementia diagnosis. Neuroimaging techniques such as MRI and PET scans help detect early indicators of neurodegeneration and provide valuable information on the structure and function of the brain. Amyloid beta and tau proteins are two examples of biomarkers that can be found in blood or cerebrospinal fluid to monitor the course of a disease. Additionally, cognitive evaluations and neuropsychological exams aid in identifying certain deficiencies and assessing cognitive capacities. Healthcare professionals can identify patients more accurately by combining these methods, which may allow for earlier interventions that could reduce the disease's progression.

Track 14-1: Genetic Testing

Track 14-2: Artificial Intelligence and Machine Learning

Track 14-3: Cognitive Assessment Tools

Track 14-4: Biomarkers

Track 14-5: Neuroimaging

Session 15: Treatment Modalities for Dementia

Although dementia currently has no known cure, there are a number of treatments that can help control symptoms, improve quality of life, and potentially delay the disease's progression. These treatments include medications like cholinesterase inhibitors and memantine, which can improve cognitive function and behavior. Exercise, social engagement, and cognitive stimulation therapy are examples of non-medical techniques that can be beneficial. Crucial components of dementia care also include providing supportive care, addressing underlying medical issues, and adjusting medication.

Track 15-1: Experimental Therapies

Track 15-2: Dietary Interventions

Track 15-3: Supportive Care

Track 15-4: Non-Pharmacological Interventions

Track 15-5: Pharmacological Interventions

Session 16: Causes and Prevention of Dementia

A progressive loss of cognitive function brought on by a number of circumstances is known as dementia. Given that the chance of acquiring dementia rises with age, age is a significant risk factor. A family history of dementia is one example of a genetic component that could play a role. Diet, exercise, and mental stimulation are examples of lifestyle decisions that can impact risk. Vascular dementia is more likely to occur in those with diabetes, high blood pressure, and heart disease. Adopting a healthy lifestyle that includes regular exercise, a balanced diet, and cognitive activities can help reduce the risk even if there is no known solution. In order to control symptoms and reduce the progression of the condition, early diagnosis and action are essential.

Track 16-1: Environmental Factors

Track 16-2: Vascular Risk Factors

Track 16-3: Lifestyle Factors

Track 16-4: Genetic Factors

Track 16-5: Age-Related Changes

Session 17: Dementia Care, Practice and Awareness

Improving the quality of life for people with dementia and those who care for them requires dementia care, awareness, and practice. A multidisciplinary approach is necessary for effective care, with an emphasis on symptom management, behavioral difficulties, and support. Raising awareness is essential for lowering stigma, promoting early detection, and enabling prompt intervention. Understanding dementia, seeking early medical examination, and getting the appropriate care can help people and families deal with this challenging illness more successfully.

Track 17-1: Environmental Factors

Track 17-2: Vascular Risk Factors

Track 17-3: Lifestyle Factors

Track 17-4: Genetic Factors

Track 17-5: Age-Related Changes

Session 18: Case Reports in Dementia

Advances in dementia diagnosis have significantly improved early detection and precision. Early indicators of neurodegeneration can be found with the help of neuroimaging techniques such as MRI and PET scans, which provide crucial information about the structure and function of the brain. Biomarkers, such as tau and amyloid beta proteins, can be found in blood or cerebrospinal fluid to monitor the course of a disease. Cognitive testing and neuropsychological examinations also aid in identifying certain deficiencies and assessing cognitive capacities. Combining these methods allows medical professionals to identify patients more accurately and implement interventions early, which may help halt the disease's course.

Track 18-1: Atypical Presentations

Track 18-2: Novel Treatment Approaches

Track 18-3: Case Series

Track 18-4: Case Reports in Specific Subtypes of Dementia

Track 18-5: Case Reports in Special Populations

Market Analysis

The global dementia treatment market is experiencing notable growth, driven by an aging population and the increasing prevalence of neurodegenerative diseases. The market is expected to reach $17.06 billion by 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.68% from 2024 to 2030. Alzheimer's disease, the most common form of dementia, holds a significant share of the market.

Despite promising advancements in research and development, challenges such as high drug development costs and limited treatment options remain. The focus is on early diagnosis, disease-modifying therapies, personalized medicine, and non-pharmacological interventions to enhance the lives of those living with dementia.

Key factors driving market growth include:

Aging Population: With increasing life expectancy, the global number of individuals with dementia is rising.
Increasing Prevalence of Neurodegenerative Diseases: The growing incidence of conditions like Alzheimer's and Parkinson's diseases is fueling the demand for effective treatments.
Advancements in Research and Development: Ongoing research is yielding new diagnostic tools, therapeutic interventions, and preventive strategies.
Rising Healthcare Expenditure: Higher investment in healthcare infrastructure and increased healthcare spending is supporting market growth.

However, several challenges hinder progress:

High Drug Development Costs: The complex and expensive process of developing effective dementia treatments is a significant barrier.
Limited Treatment Options: Existing treatments mainly address symptoms, rather than tackling the root causes of dementia.
Regulatory Hurdles: Strict regulatory requirements can delay the approval of new drugs and therapies.

To overcome these challenges and take advantage of emerging opportunities, the industry is focusing on:

Early Diagnosis and Intervention: Detecting and intervening early can greatly improve outcomes for individuals with dementia.
Disease-Modifying Therapies: Efforts are focused on developing drugs that can slow or stop disease progression.
Personalized Medicine: Treatment approaches tailored to individual patients based on their genetic and biological makeup.
Non-Pharmacological Interventions: Lifestyle changes, cognitive stimulation, and physical exercise play a vital role in managing dementia.

Organizing committee members

Dr. Hans von Holst

Karolinska Institute Hospital, Sweden

Dr. George N. Shilau,

MD, Assistant Professor

Republican Clinic Medical Center, Russia

Dr. Santiago Restrepo

American University Corporation, Colombia

Dr. Alexandra Ferreira-Valente

ISPA Institute, Portugal

Dr. Sam Vaknin

Professor

Southern Federal University, Russia

Dr. Felice Corona

University of Salerno, Italy

Prof. W S El MasrI

Midland Centre for Spinal Injuries, UK

Dr. Andrew Sofin

Canadian Association for Marriage & Family, Canada

Dr. Alain Fymat

International Institute of Medicine and Science, USA

Renowned Speakers

Dr. Alireza Heidari

Head of Cancer Research Institute (CRI), USA

Dr. Edward Snowden

American Autism Association, USA

Dr. Merlin Larson

University of Salamanca, Spain

Victor Manuel Neira A

Dalhousie University, Canada

To Collaborate Scientific Professionals around the World

Conference Date	May 08-09, 2025
Poster Oppurtunity	Available
e-Poster Oppurtunity	Available

Testimonials

Eliaz Babaev

Arobella Medical LLC, USA

“Conference was organized very well with specialists, scientists from academics and companies, I am very much happy to make a presentation here because of the topic, all presenters are valuable people in the dementia care field.”